Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GRM8 | O00222 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753721 | 0.80 | PTPRC (0.41) | PTPRCMAPTNPSR1KMT2AALDH1A1 | |
| SCHEMBL693608 | 0.80 | PTPRC (0.45) | PTPRCTSHRMAPTNPSR1KMT2A | |
| SCHEMBL11537268 | 0.77 | PTPRC (0.39) | PTPRCMAPTNPSR1KMT2AALDH1A1 | |
| SCHEMBL14445422 | 0.76 | PTPRC (0.41) | PTPRCTSHRMAPTNPSR1KMT2A | |
| SCHEMBL826939 | 0.72 | — | — | |
| SCHEMBL9320506 | 0.72 | KCNH2 (0.47) | ALDH1A1 | |
| SCHEMBL14445423 | 0.71 | RPS6KB2 (0.45) | PTPRCMAPTNPSR1KMT2AALDH1A1 | |
| SCHEMBL2136898 | 0.71 | XDH (0.40) | PTPRCMAPTNPSR1KMT2A | |
| SCHEMBL2016370 | 0.70 | PTPRC (0.46) | PTPRCTSHRMAPTNPSR1KMT2A | |
| SCHEMBL9005006 | 0.70 | PTPRC (0.46) | PTPRCTSHRMAPTNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-3810595-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112334462-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| CN-102448952-B | Antiviral compounds and uses thereof | ABBVIE (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2421845-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LAB (US) | 2013-04-17 | — | — | EP | disclosed |
| CN-102448952-A | Antiviral compounds and uses thereof | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2421845-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Abbott Laboratories (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010111437-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | PTPRC 576/4885TSHR 4664/4885MAPT 4152/4885 |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | PTPRC 4067/4885TSHR 4632/4885MAPT 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.